OCT 05, 2016 12:00 PM PDT

Sensitive and Specific, Multiplex, Real-Time PCR Assays for Assessing the Abundance of Extremely Rare Mutations Associated with Cancer Diagnosis, Prognosis, and Therapy

Speaker
  • Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University
    Biography
      Fred Russell Kramer is Professor of Microbiology and Molecular Genetics at the New Jersey Medical School, and has been a Principal Investigator at the Public Health Research Institute for the past 25 years. He graduated from the University of Michigan in 1964 and received his doctorate from the Rockefeller University in 1969. He was on the faculty of the Department of Genetics and Development at Columbia University College of Physicians and Surgeons for 17 years and has been a Research Professor and Adjunct Professor in the Department of Microbiology at New York University School of Medicine for the past 24 years.

    Abstract

    Real-time multiplex PCR assays are potentially the most rapid, most sensitive,
    and least expensive way to assess the abundance of mutant DNA fragments present in liquid biopsies; provided that a way is found to selectively amplify rare mutant fragments without amplifying abundant related wild-type fragments; and provided that the amplicons generated from different mutants that occur in the same or an adjacent codon are prevented from forming heteroduplexes that interfere with exponential amplification, obscuring the threshold values of the rarer mutants.  “SuperSelective” PCR primers, due to their unique design, are extraordinarily specific, able to selectively initiate the synthesis of amplicons
    on ten mutant DNA fragments in the presence of 1,000,000 wild-type DNA fragments,
    even though the only difference between the mutant and the wild-type is a single-nucleotide polymorphism.  Moreover, each SuperSelective primer that is specific for a particular mutation possesses a unique 5' tag sequence that is incorporated into the resulting amplicons and detected in real-time by differently colored molecular beacon probes. 
    Each SuperSelective primer specific for a particular mutation also possesses a unique “bridge” sequence that assures that each primer only copies its intended amplicon,
    and that creates a single-stranded bubble in heteroduplexes that enables the rarest amplicons to be independently exponentially amplified.  And finally, the inclusion of primers for a wild-type reference gene fragment, enables the abundance of each type of mutant
    DNA fragment to be assessed (without measuring the amount of DNA in the sample)
    by determining the difference between its threshold value and the threshold value of
    the reference gene.
     


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 05, 2016 12:00 PM PDT

    Sensitive and Specific, Multiplex, Real-Time PCR Assays for Assessing the Abundance of Extremely Rare Mutations Associated with Cancer Diagnosis, Prognosis, and Therapy


    Specialty

    Molecular Diagnostics

    Cancer Research

    Biotechnology

    Clinical Diagnostics

    Molecular Biology

    Clinical Research

    Cell Biology

    Immunology

    Cell Culture

    Dna Sequencing

    Gene Expression

    Cancer Diagnostics

    Virology

    Lab Automation

    Dna

    Geography

    North America57%

    Asia29%

    Europe14%

    Registration Source

    Website Visitors100%

    Job Title

    Student33%

    Clinical Laboratory Scientist33%

    Educator/Faculty17%

    Medical Laboratory Technician17%

    Organization

    Academic Institution43%

    Hospital29%

    Clinical Laboratory29%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more